Cohere is where secure and sovereign AI meets practical business solutions. A foundational generative AI lab building specialized LLMs and agent solutions for the most sophisticated, respected, and demanding enterprises in the world. | Empowering enterprises with private, powerful foundational models and AI solutions. | Cohere: Safe, flexible, and built for business. Cohere offers a vertically integrated, all-in-one AI platform designed for government agencies and enterprises in regulated industries. Our platform accelerates AI strategies with proprietary models and personalized agentic solutions, offering cutting-edge multilingual capabilities, advanced retrieval, and a modern AI workspace — all within a single, secure environment.
Chiesi Global Rare Diseases
Chiesi Global Rare Diseases is a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases. As a family business, Chiesi Group strives to create a world where it is common to have a therapy for all diseases and acts as a force for good, for society and the planet. The goal of the Global Rare Diseases unit is to ensure equal access so as many people as possible can experience their most fulfilling life. The unit collaborates with the rare disease community around the globe to bring voice to underserved people in the health care system. For more information visit www.chiesirarediseases.com.
Calliditas Therapeutics
Calliditas is dedicated to expanding treatment options and establishing new standards of care for people with rare diseases. By drawing on our expertise in pharmaceutical product development and leveraging our strategic partnerships, we quickly and efficiently identify, develop, and market a pipeline of innovative medicines that can improve the lives of patients. Recently, we successfully commercialized our lead candidate in the United States, and in collaboration with our partners, launched in Europe, with plans to seek approval in Asia.
Burna Ai
Burna AI is a clinical intelligence platform that uses AI to automate CTCAE adverse event grading and streamline oncology workflow by reading clinical notes, labs, and patient data to deliver accurate, evidence-cited adverse event assessments in seconds. Built for cancer care teams, clinical trials, and oncology practices, it improves consistency, saves time, and enhances documentation quality.
Boehringer Ingelheim Pharmaceuticals, Inc./Lilly USA
Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA welcome you and look forward to the opportunity to share the latest clinical information on our products. Visit http://us.boehringer-ingelheim.com or www.lilly.com. Follow us on twitter at @boehringerus. Our Diabetes Alliance also welcomes you to visit https://pro.boehringer-ingelheim.com/us/products/jardiance/.